Sino Green Land Corporation

Item 1.01 Entry Into a Material Definitive Agreement. Xing Da Plastics Sdn. Bhd. Stock Purchase Agreement On August 7, 2026, Sino Green Land Corporation (the “Company”) entered into a stock purchase agreement (the “Xing Da SPA”) with the equity holders (identified in the Xing Da SPA, each, a “Xing Da Seller,” and collectively, the “Xing Da Sellers”) of Xing Da Plastics Sdn. Bhd., a private limited company (Sendirian Berhad) organized under the laws of Malaysia, with its principal place of business in Klang, Selangor, Malaysia ( “Xing Da”). Pursuant to the Xing Da SPA, the Xing Da Sellers agreed to sell to the Company, free and clear of all liens, shares representing collectively 60% of the issued and outstanding capital stock of Xing Da on a fully diluted basis (the “Xing Da Target Shares”), in exchange for an aggregate of 4,800,000 shares of the Company’s common stock, par value $0.60 per share (the “Xing Da Stock Consideration”). Following the transaction, the Xing Da Sellers retained the remaining 40% of Xing Da’s issued and outstanding capital stock pro rata in accordance with their respective percentages. The Xing Da Stock Consideration shall be issued to the Xing Da Sellers in three (3) tranches: (a) First Tranche: 960,000 shares of the Company’s common stock (20% of the Xing Da Stock Consideration), issuable at the Closing (as defined in the Xing Da SPA); (b) Second Tranche: 1,920,000 shares of the Company’s common stock (40% of the Xing Da Stock Consideration), issuable upon satisfaction of certain conditions, including, without limitation, a specified date (the date that is three (3) months following the Closing) or achievement of specified milestones (the “Second Tranche Trigger Condition”); and (c) Third Tranche: 1,920,000 shares of the Company’s common stock (40% of the Xing Da Stock Consideration), issuable upon satisfaction of certain conditions, including, without limitation, a specified date (the date that is six (6) months following the Closing) or achievement of specified milestones (the “Third Tranche Trigger Condition”). No fractional shares of the Company’s common stock shall be issued in any tranche. Notwithstanding the foregoing, the issuance of the Second Tranche and Third Tranche shall be accelerated upon the occurrence of any of the following events within the first three (3) months following the Closing: (i) a change of control of the Company; (ii) a material breach by the Company of the Xing Da SPA; (iii) the termination of Huang Gangkan as a director of Xing Da without cause; or (iv) the death or incapacity of Huang Gangkan. If any such acceleration event occurs after the three (3) month period following the Closing, the Second Tranche and Third Tranche shall continue to be issued in accordance with the time-based schedule described above. In the event that a milestone is not achieved, the corresponding shares shall be subject to forfeiture, carryover to the next tranche, proration based on partial achievement, or a cure period, as determined by the parties in accordance with the terms of the Xing Da SPA. Pursuant to the Xing Da SPA, the Xing Da Sellers and Xing Da jointly and severally made certain representations and provided certain warranties to the Company relating to, among other things: (a) the authorization, performance and enforceability of the agreement; (b) Xing Da and each subsidiary of Xing Da being in good standing; (c) the capitalization, financial statements, taxes, real property and title to assets, intellectual property, compliance with laws and permits, employee matters, labor matters, environmental matters, insurance, transactions with related party and investment matters of Xing Da; (d) that there are no pending or threatened actions preventing the transactions contemplated by the agreement from being completed; and (e) that no brokers, finders or investment banks fees are required to be paid in connection with the transactions contemplated by the Xing Da SPA. Pursuant to the Xing Da SPA, the Company made certain representations and provided certain warranties to the Xing Da Sellers and Xing Da relating to, among other things: (a) the authorization, performance and enforceability of the agreement; (b) the Company being in good standing; (c) the Company has, or will have prior to the issuance of each tranche of the Xing Da Stock Consideration, a sufficient number of authorized and unissued shares of the Company’s common stock to satisfy the issuance of the Xing Da Stock Consideration in full; (d) the Company is acquiring the Xing Da Target Shares for its own account and for investment purposes, and not with a view to resale or distribution in violation of applicable securities law; (e) that there are no pending or threatened actions preventing the transactions contemplated by the agreement from being completed; (f) that no brokers, finders or investment banks fees are required to be paid in connection with the transactions contemplated by the Xing Da SPA; and (g) the validity of the Xing Da Stock Consideration issuance. The closing of the Xing Da SPA is subject to the satisfaction (or waiver) of certain closing conditions, including (a) the representations and warranties of the Xing Da Sellers, Xing Da and the Company shall be true and correct; (b) the Xing Da Sellers, Xing Da and the Company shall have performed, in all material respects, its/their covenants required to be performed; (c) no Material Adverse Effect (as defined in the Xing Da SPA) shall have occurred; (d) all consents and approvals, including any approvals required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), shall have been obtained; (e) no order prohibiting the transactions contemplated by the Xing Da SPA shall be in effect; and (f) the Xing Da Sellers shall have delivered the closing deliverables, including all Xing Da Target Shares free and clear of all liens; the Company shall have delivered the First Tranche of the Xing Da Stock Consideration and the closing deliverables. The Xing Da SPA may be terminated prior to the Closing: (a) by mutual written consent of the Company and the Xing Da Sellers’ representative; (b) by either the Company or the Xing Da Sellers’ representative if the Closing has not occurred by the Outside Date (as defined in the Xing Da SPA), provided that the terminating party is not then in material breach; (c) by either party if a governmental authority has issued a final, non-appealable order prohibiting the transactions; or (d) by either party for the other party’s material breach that remains uncured for ten (10) business days following written notice. The foregoing description of the SPA is not complete and is subject to, and qualified in its entirety by reference to the attached Exhibit 10.1 hereto, which are incorporated in this Item 1.01 by reference in their entirety. Invent Fortune Stock Purchase Agreement On August 7, the Company entered into a stock purchase agreement (the “Invent Fortune SPA”) with the equity holders (identified in the Invent Fortune SPA, each, a “Invent Fortune Seller,” and collectively, the “Invent Fortune Sellers”) of Invent Fortune, a private limited company (Sendirian Berhad) organized under the laws of Malaysia, with its principal place of business in Semenyih, Selangor, Malaysia (“Invent Fortune”). Pursuant to the Invent Fortune SPA, the Invent Fortune Sellers agreed to sell to the Company, free and clear of all liens, all shares of the issued and outstanding capital stock of Invent Fortune on a fully diluted basis (the “Invent Fortune Target Shares”), in exchange for an aggregate of 21,916,700 shares of the Company’s common stock, par value $0.60 per share (the “Invent Fortune Stock Consideration”). The Invent Fortune Stock Consideration shall be issued to the Invent Fortune Sellers in three (3) tranches: (a) First Tranche: 4,383,340 shares of the Company’s common stock (20% of the Invent Fortune Stock Consideration), issuable at the Closing (as defined in the Invent Fortune SPA); (b) Second Tranche: 8,766,680 shares of the Company’s common stock (40% of the Invent Fortune Stock Consideration), issuable upon satisfaction of certain conditions, including, without limitation, a specified date (the date that is three (3) months following the Closing) or achievement of specified milestones (the “Second Tranche Trigger Condition”); and (c) Third Tranche: 8,766,680 shares of the Company’s common stock (40% of the Invent Fortune Stock Consideration), issuable upon satisfaction of certain conditions, including, without limitation, a specified date (the date that is six (6) months following the Closing) or achievement of specified milestones (the “Third Tranche Trigger Condition”). No fractional shares of the Company’s common stock shall be issued in any tranche. Notwithstanding the foregoing, the issuance of the Second Tranche and Third Tranche shall be accelerated upon the occurrence of any of the following events within the first three (3) months following the Closing: (i) a change of control of the Company; (ii) a material breach by the Company of the Invent Fortune SPA; (iii) the termination of Kee Seng Yam as a director of Invent Fortune without cause; or (iv) the death or incapacity of Kee Seng Yam. If any such acceleration event occurs after the three (3) month period following the Closing, the Second Tranche and Third Tranche shall continue to be issued in accordance with the time-based schedule described above. In the event that a milestone is not achieved, the corresponding shares shall be subject to forfeiture, carryover to the next tranche, proration based on partial achievement, or a cure period, as determined by the parties in accordance with the terms of the Invent Fortune SPA. Pursuant to the Invent Fortune SPA, the Invent Fortune Sellers and Invent Fortune jointly and severally made certain representations and provided certain warranties to the Company relating to, among other things: (a) the authorization, performance and enforceability of the agreement; (b) Invent Fortune and each subsidiary of Invent Fortune being in good standing; (c) the capitalization, financial statements, taxes, real property and title to assets, intellectual property, compliance with laws and permits, employee matters, labor matters, environmental matters, insurance, transactions with related party and investment matters of Invent Fortune; (d) that there are no pending or threatened actions preventing the transactions contemplated by the agreement from being completed; and (e) that no brokers, finders or investment banks fees are required to be paid in connection with the transactions contemplated by the Invent Fortune SPA. Pursuant to the Invent Fortune SPA, the Company made certain representations and provided certain warranties to the Invent Fortune Sellers and Invent Fortune relating to, among other things: (a) the authorization, performance and enforceability of the agreement; (b) the Company being in good standing; (c) the Company has, or will have prior to the issuance of each tranche of the Invent Fortune Stock Consideration, a sufficient number of authorized and unissued shares of the Company’s common stock to satisfy the issuance of the Invent Fortune Stock Consideration in full; (d) the Company is acquiring the Invent Fortune Target Shares for its own account and for investment purposes, and not with a view to resale or distribution in violation of applicable securities law; (e) that there are no pending or threatened actions preventing the transactions contemplated by the agreement from being completed; (f) that no brokers, finders or investment banks fees are required to be paid in connection with the transactions contemplated by the Invent Fortune SPA; and (g) the validity of the Invent Fortune Stock Consideration issuance. The closing of the Invent Fortune SPA is subject to the satisfaction (or waiver) of certain closing conditions, including (a) the representations and warranties of the Invent Fortune Sellers, Invent Fortune and the Company shall be true and correct; (b) the Invent Fortune Sellers, Invent Fortune and the Company shall have performed, in all material respects, its/their covenants required to be performed; (c) no Material Adverse Effect (as defined in the Invent Fortune SPA) shall have occurred; (d) all consents and approvals, including any approvals required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), shall have been obtained; (e) no order prohibiting the transactions contemplated by the Invent Fortune SPA shall be in effect; and (f) the Invent Fortune Sellers shall have delivered the closing deliverables, including all Invent Fortune Target Shares free and clear of all liens; the Company shall have delivered the First Tranche of the Invent Fortune Stock Consideration and the closing deliverables. The Invent Fortune SPA may be terminated prior to the Closing: (a) by mutual written consent of the Company and the Invent Fortune Sellers’ representative; (b) by either the Company or the Invent Fortune Sellers’ representative if the Closing has not occurred by the Outside Date (as defined in the Invent Fortune SPA), provided that the terminating party is not then in material breach; (c) by either party if a governmental authority has issued a final, non-appealable order prohibiting the transactions; or (d) by either party for the other party’s material breach that remains uncured for ten (10) business days following written notice. The foregoing description of the Invent Fortune SPA is not complete and is subject to, and qualified in its entirety by reference to the attached Exhibit 10.2 hereto, which are incorporated in this Item 1.01 by reference in their entirety. Item 3.02. Unregistered Sales of Equity Securities. The disclosure set forth in Item 1.01 hereof is hereby incorporated by reference into this Item 3.02. The issuance of the Company’s common stock is intended to be exempt from registration pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), since the foregoing issuances will not involve a public offering, the recipients have confirmed that they are “accredited investors”, and the recipients will acquire the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered without any general solicitation by us or our representatives. The securities will be subject to transfer restrictions, and the certificates evidencing the securities will contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration or pursuant to an exemption therefrom.